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Reactivating apoptosis is a major goal of cancer research, and MCL-1 has emerged as a primary pharmaco-
logical target. A screen for small molecules that could compete with stabilized helical peptides for MCL-1
binding yielded small molecule MIM1 (see the article by Cohen et al. in this issue of Chemistry & Biology).
MIM1 selectively targets MCL-1, and can kill MCL-1-dependent leukemia cells.Cancer is caused by an accumulation of
mutations in key pathways, resulting in
the acquisition of specific growth charac-
teristics that result inmalignancy (Hanahan
and Weinberg, 2011). One of these is
subversion of apoptosis, the cell’s pro-
grammed death pathway. Apoptosis
signaling senses severe DNA damage
and other insults and induces cell suicide,
limiting genomic instability and preventing
malignancy. Thus, reestablishing apo-
ptosis has emerged as a key therapeutic
strategy for combating a variety of solid
tumors and leukemias(Lessene et al.,
2008). Despite its promise, this approach
is a difficult one for traditional medicinal
chemistry because several of the key
signaling events are protein-protein inter-
actions, such as those among pro-
apoptotic and anti-apoptotic proteins in
the BCL-2 family (Verdine and Walensky,
2007). New approaches to targeting these
difficult interactions have generated potent
inhibitors of BCL-2 proteins, and many of
these inhibitors are being developed as
therapies. Two notable examples of thesenew approaches are fragment-based
drug design, which yielded the small
molecule ABT-737 and its analogs (Olters-
dorf et al., 2005; Tseet al., 2008), and ‘‘helix
stapling,’’ which yieldedmodified peptides
called SAHBs (stabilized a helices of Bcl-2
domains) (Stewart et al., 2010; Walensky
et al., 2004). In this issue of Chemistry &
Biology, Cohen et al. (2012) use a SAHB
in a high-throughput screen to find small
molecules that displace the SAHB from its
binding partner. In doing so, they suggest
that straightforward screening efforts may
benefit from the application of compounds
developed using more non-traditional
approaches.
The peptide used in the study is SAHBA,
which is a stapled analog of a helix from
the BCL-2 family protein MCL-1. Previous
work had shown that this modified
peptide binds MCL-1 with high affinity
and high selectivity over other BCL-2
family members (Stewart et al., 2010).
MCL-1 is an anti-apoptotic BCL-2 protein
whose overexpression drives diverse
cancers (Beroukhim et al., 2010). Inhibi-tors such ABT-737 and its analogs target
other BCL-2 family proteins but are not
effective against cells that overexpress
MCL-1. This indicates that inhibition of
both MCL-1 and BCL-2/BCL-XL may be
the best approach for reactivating
apoptosis (van Delft et al., 2006). In this
light, understanding MCL-1 specificity
and developing new classes of MCL-1
inhibitors are clear priorities for apoptosis
researchers.
The authors screened over 70,000
small molecules to find those that could
displace a fluorescently labeled SAHBA
from the BH3-binding domain of MCL-1.
These were further screened to identify
compounds that could not displace a
fluorescently labeled BAD-BH3 peptide
from the BH3-binding domain of BCL-
XL. Further screens checked the modes
of binding and the dose reponses of the
hits, and 28 compounds were carried
forward to liposome- and cell-based
assays that test functional activation of
apoptotic membrane permeabilization. Of
the compounds that performed well in
Figure 1. Who Blocks the Blockers?
Screening for inhibitors of the interaction between stapled helix SAHBA (green
helix) and the BH3-binding domain of MCL-1 (orange surface) led to the
discovery of small molecule MIM1. MIM1 inhibits MCL-1 with unprecedented
selectivity over other BCL family proteins,and can kill MCL-1-dependent
leukemia cells. The structural model was reproduced with permission from
L. Walensky.
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Previewsthese assays, the authors
selected MIM1 as their most
promising hit (Figure 1).
Further biophysical, lipo-
somal, and cell culture assays
revealed that MIM1 has tight
selectivity for MCL-1 over
other BCL-2 proteins, and the
authors demonstrate a con-
vincing contrast between
MIM1 and ABT-737as proto-
type MCL-1-specific and
BCL-XL-specific inhibitors,
respectively.
While MIM1 is a welcome
new molecule in the struggle
to target MCL-1, several
questions remain after this
initial report. The structure-
activity data provides evi-
dence of specific binding butdo not shed much light on those aspects
of MIM-1 that are truly responsible for
the observed inhibition. Likewise, the
mutagenesis and structural data attest
that MIM1 does directly bind MCL-1 in
a manner that blocks its BH3-binding
groove, but the specific binding model
presented will likely undergo some refine-
ment once additional data is collected.
Even though the molecular-level details
remain to be elucidated, the biological
assays leave little doubt that MIM1 is
among the rare compounds that can
selectively target MCL-1 and can kill
MCL-1-dependent leukemia cells. Theauthors observe synergistic cytotoxicity
when MIM-1 is co-applied with ABT-737,
which hints at a promising road ahead
for combination therapies targeting
multiple BCL-2 family members. Given
that the most desired profile of an
apoptosis sensitizer may be one that
blocks both MCL-1 and BCL-2/BCL-XL,
it will be interesting to see whether
screens such as these can uncover addi-
tional inhibitors with dual specificity. In the
meantime, compounds such as MIM1
represent long-awaited small-molecule
tools for selective inhibition of important
BCL-2 family proteins.Chemistry & Biology 19, September 21, 2012 ª2012 ElseviREFERENCES
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